Luo passes and applies to FDA again new medicine of arthritis

Luo passes and applies to FDA again new medicine of arthritis
Yeah finance and economics reports Roche Group and claims today, already to American food and medicine administration bureau (FDA) again on August 3 Having filed the listing, applying of new medicine Actemra of rheumatic arthritis, this medicines sanctioned being listed in Japan since 2005, having obtained approval in Europe too in January of this year, India, Brazil, Switzerland, Australia released the pass to it too.
Luo company say FDA confirm, finish two the intersection of examination and approval and work to submit the application within 6 months already, last July, FDA the intersection of arthritis and medicine consultative committee agree with 10 ticket once and 1 ticket it objects to to be certainly like this new medicine. Will it be April 2008, Japan sanction it treat rheumatic arthritis again and and specially taking place whole body type arthritis in childhood childhood. In view of the above, the analyst thinks it probably becomes medicine in great demand.
The Chinese relevant person of Luo says to Yeah finance and economics, Actemra does not still land time tables of the Chinese market at present. (The source of this text: Yeah finance and economics Author: Chen Ran)

|